Modulation of Colorectal Cancer Risk by Polymorphisms in 51Gln/His, 64Ile/Val, and 148Asp/Glu of APEX Gene; 23Gly/Ala of XPA Gene; and 689Ser/Arg of ERCC4 Gene

Table 7

The distribution of genotypes and the analysis of the odds ratio (OR) for gene-gene interactions in analyzed polymorphisms in patients with colorectal cancer (CRC) and the control group. Shown are only pairs that modulate the risk at a statistically significant level. All partial results for the gene-gene interaction are shown in the supplementary materials.

Gene-gene interaction	Genotype	Patients	Controls	OR (95% CI)
51Gln/His APEX-64Ile/Val APEX	Gln/His-Val/Val	55	32	2.266 (1.120–4.585)	0.022
51Gln/His APEX-148Asp/Glu APEX	Gln/His-Asp/Glu	174	102	2.003 (1.091–3.676)	0.023
	Gln/His-Glu/Glu	8	26	0.361 (0.137–0.951)	0.036
	His/His-Asp/Asp	6	28	0.252 (0.089–0.714)	0.007
51Gln/His APEX-23Gly/Ala XPA	Gln/His-Gly/Gly	6	35	0.220 (0.078–0.622)	0.003
	Gln/His-Gly/Ala	193	98	2.532 (1.362–4.707)	0.003
	His/His-Gly/Ala	30	8	4.821 (1.835–12.670)	0.001
51Gln/His APEX-689Ser/Arg ERCC4	Gln/His-Arg/Arg	39	24	2.464 (1.247–4.870)	0.009
64Ile/Val APEX-148Asp/Glu APEX	Ile/Val-Asp/Asp	10	27	0.403 (0.170–0.955)	0.036
	Val/Val-Asp/Glu	59	18	3.567 (1.765–7.211)	0.0003
64Ile/Val APEX-23Gly/Ala XPA	Ile/Val-Gly/Gly	9	37	0.269 (0.103–0.700)	0.006
	Ile/Val-Ala/Ala	6	23	0.288 (0.097–0.859)	0.022
	Val/Val-Gly/Ala	62	14	4.895 (2.093–11.445)	0.0001
148Asp/Glu APEX-23Gly/Ala XPA	Asp/Asp-Gly/Ala	26	58	0.399 (0.176–0.902)	0.025
	Asp/Glu-Gly/Gly	8	46	0.155 (0.056–0.424)	0.0001
	Asp/Glu-Gly/Ala	218	81	2.392 (1.164–4.915)	0.015
148Asp/Glu APEX-689Ser/Arg ERCC4	Asp/Asp-Ser/Arg	21	48	0.844 (0.370–1.924)	0.689
	Asp/Asp-Arg/Arg	13	13	1.929 (0.707–5.263)	0.198
	Asp/Glu-Ser/Ser	69	49	2.716 (1.293–5.704)	0.007
23Gly/Ala XPA-689Ser/Arg ERCC4	Gly/Ala-Ser/Ser	76	57	2.333 (1.061–5.131)	0.032
	Gly/Ala-Ser/Arg	135	77	3.068 (1.431–6.577)	0.003
	Gly/Ala-Arg/Arg	47	16	5.141 (2.073–12.749)	0.0003